Market Overview:
The global non-Hodgkin lymphoma (NHL) market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to factors such as increasing incidence of NHL, rising awareness about NHL, and technological advancements in the diagnosis and treatment of NHL. However, the high cost of treatment is a major restraint on the growth of this market. The standard segment is expected to dominate the global non-Hodgkin lymphoma (NHL) market during the forecast period owing to its large patient population and growing demand for better treatments options.
 Industry Outlook.svg)
Product Definition:
Non Hodgkin Lymphoma (NHL) is a type of cancer that starts in the lymphatic system. The lymphatic system is a network of organs and vessels that helps fight infection and remove waste from the body. NHL can affect any part of the lymphatic system, including the glands (lymph nodes), spleen, liver, bone marrow, or other organs.
Standard:
The global standard market is expected to witness significant growth over the forecast period owing to increasing demand for early diagnosis and treatment of diseases. Rise in number of patients suffering from Non-Hodgkin lymphoma (NHL) has led to an increase in demand for diagnostic procedures, which is expected to drive the growth factor during the forecast period.
Exellent:
Exellent is a cell-based therapy that helps in the regeneration of immune cells. It is used to treat patients suffering from Non-Hodgkin lymphoma (NHL), which is also known as B-cell cancer. The drug was approved by the FDA for treatment of this disease in 2008 and it gained popularity owing to its fast acting properties, which help patients experience fewer side effects.
Application Insights:
Based on the application, the global market is segmented into hospital-based and clinic-based. The hospital based segment held a larger share of over 70% in 2017. This is due to factors such as availability of advanced treatment facilities in major countries, such as Germany, U.K., France and Russia which have prominent healthcare sectors that are equipped to handle Non-hodgkin lymphoma cases effectively. Moreover, increasing awareness about NHL among people especially in developed countries like U.S., Canada and Australia is expected to boost growth during the forecast period for this market owing to high incidence rates of cancer across these regions which has resulted in increased demand for effective treatment options globally thereby driving growth for this segment over the forecast period for this market with CAGR around 7%.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to high adoption of immunotherapy drugs, presence of key manufacturers such as Pfizer Inc., and increased funding by government entities. For instance, in 2014’s fiscal year, the U.S. government invested USD X million for research on blood cancers such as leukemia and lymphoma at the National Cancer Institute (NCI).
Growth Factors:
- Increasing incidence of NHL
- Growing awareness about NHL and its treatment options
- Rising demand for better and more effective therapies for NHL patients
- Technological advancements in the diagnosis and treatment of NHL
- increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Non Hodgkin Lymphoma (NHL) Market Research Report
By Type
Standard, Exellent
By Application
Hosptial, Clinic
By Companies
F. Hoffmann-La Roche, Johnson & Johnson, Merck, Bristol Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Bayer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
206
Number of Tables & Figures
145
Customization Available
Yes, the report can be customized as per your need.
Global Non Hodgkin Lymphoma (NHL) Market Report Segments:
The global Non Hodgkin Lymphoma (NHL) market is segmented on the basis of:
Types
Standard, Exellent
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hosptial, Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- F. Hoffmann-La Roche
- Johnson & Johnson
- Merck
- Bristol Myers Squibb
- Celgene
- Eli Lilly
- GlaxoSmithKline
- Bayer
 Market Overview.svg)
Highlights of The Non Hodgkin Lymphoma (NHL) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Standard
- Exellent
- By Application:
- Hosptial
- Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Non Hodgkin Lymphoma (NHL) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Non Hodgkin lymphoma (NHL) is a type of cancer that affects the lymphatic system. NHL can occur anywhere in the body, but most often occurs in the neck, chest, and lungs. NHL is treated with chemotherapy and radiation therapy.
Some of the key players operating in the non hodgkin lymphoma (nhl) market are F. Hoffmann-La Roche, Johnson & Johnson, Merck, Bristol Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Bayer.
The non hodgkin lymphoma (nhl) market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Non Hodgkin Lymphoma (NHL) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Non Hodgkin Lymphoma (NHL) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Non Hodgkin Lymphoma (NHL) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Non Hodgkin Lymphoma (NHL) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Non Hodgkin Lymphoma (NHL) Market Size & Forecast, 2020-2028
4.5.1 Non Hodgkin Lymphoma (NHL) Market Size and Y-o-Y Growth
4.5.2 Non Hodgkin Lymphoma (NHL) Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Standard
5.2.2 Exellent
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hosptial
6.2.2 Clinic
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Non Hodgkin Lymphoma (NHL) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Non Hodgkin Lymphoma (NHL) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Standard
9.6.2 Exellent
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hosptial
9.10.2 Clinic
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Standard
10.6.2 Exellent
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hosptial
10.10.2 Clinic
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Standard
11.6.2 Exellent
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hosptial
11.10.2 Clinic
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Standard
12.6.2 Exellent
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hosptial
12.10.2 Clinic
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Standard
13.6.2 Exellent
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hosptial
13.10.2 Clinic
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Non Hodgkin Lymphoma (NHL) Market: Competitive Dashboard
14.2 Global Non Hodgkin Lymphoma (NHL) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 F. Hoffmann-La Roche
14.3.2 Johnson & Johnson
14.3.3 Merck
14.3.4 Bristol Myers Squibb
14.3.5 Celgene
14.3.6 Eli Lilly
14.3.7 GlaxoSmithKline
14.3.8 Bayer
